Katri, Anna
Dąbrowska, Aneta
Löfvall, Henrik
Ding, Ming
Karsdal, Morten A.
Andreassen, Kim V.
Thudium, Christian S.
Henriksen, Kim
Funding for this research was provided by:
H2020 Marie Skłodowska-Curie Actions (642720)
Article History
Received: 30 July 2018
Accepted: 11 January 2019
First Online: 22 February 2019
Ethics approval and consent to participate
: All animal experimental procedures were approved by the Animal Welfare Division of the Danish Ministry of Justice under the institutional license issued to Nordic Bioscience (2014-15-0201-00097).
: Not applicable.
: AK, MAK, KVA, CST, and KH are employees of Nordic Bioscience A/S which is a company involved in the discovery and development of biochemical biomarkers and novel therapeutic peptides, including KBPs. HL is a former employee of Nordic Bioscience A/S. KH, KVA, and MAK hold patents on KBPs. MAK and KH hold stocks in Nordic Bioscience A/S. AD and MD declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.